Extended-release Buprenorphine
Phase 3
Extended-release Buprenorphine is one of 36 therapeutic programs targeting Opioid Use Disorder. It is currently in Phase 3.
1
Indications
3
Total Trials
2
Active Trials
35
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
47 competitors in Opioid Use Disorder
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Sovaldi
GileadApproved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Cabenuva
GSKApproved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Oxycontin
PProtega
Approved
Lucemyra
BBioCorRx Pharmaceuticals Inc
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Narcan
SScienture
Approved
Anjeso
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Opioid Use Disorder3 trials
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- BBrigham and Women's Hospital